Table 2.
No. | Vaccine | Intervention site | Control Site | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | Midterm | End term | Baseline | Midterm | End term | ||||||||
Frq. | % | Frq. | % | Frq. | % | Frq. | % | Frq. | % | Frq. | % | ||
1 | BCG Immunization | 389 | 93.5 | 404 | 97.8 | 411 | 98.6 | 379 | 92.2 | 361 | 87.4 | 396 | 94.3 |
2 | Oral polio (4 doses) |
394 | 94.7 | 400 | 96.9 | 412 | 98.8 | 379 | 92.2 | 377 | 91.3 | 389 | 92.6 |
3 | Penta valent (3 doses) | 393 | 94.5 | 403 | 97.6 | 412 | 98.8 | 381 | 92.7 | 364 | 88.1 | 379 | 90.2 |
4 | Pneumococcal (3 doses) | 379 | 91.1 | 400 | 96.9 | 412 | 98.8 | 370 | 90.0 | 349 | 84.5 | 380 | 90.5 |
5 | Measles (1 dose) |
373 | 89.7 | 391 | 94.7 | 412 | 98.8 | 356 | 86.6 | 347 | 84 | 367 | 87.4 |
Base line: conducted before intervention
Midterm survey: conducted 6 months after CS intervention
End Term Survey: conducted 18 months after CS intervention